About this trial
Considering the compelling amount of studies focused on patients in the active phase of COVID-19 disease and the scarcity of studies focused on patient cured from disease aimed at evaluating the sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, the purpose of the study is to investigate, in patients recovered from COVID-19 disease: 1) whether SARS-CoV-2 infection has induced in male patients, a primary (testicular) and / or secondary (pituitary) damage to the hypothalamic-pituitary-testicular hormonal axis, structural and / or functional damage to the testis and penis, sexual dysfunction or fertility disorders; 2) the prevalence in male and female patients of chemosensory symptoms (olfactory dysfunction) and assess whether there is a correlation between the prevalence, severity, duration and eventual persistence of olfactory dysfunction and the severity of COVID-19 disease. Patients will be evaluated at baseline (at discharge from infectious and/or pneumology unit) and after 3- 12 months. A better definition of the prevalence and type of sequelae after recovery from COVID-19 disease could significantly improve the therapeutic management and long-term follow-up of these patients, with a relevant impact in terms of health resources and public health.
Eligibility criteria
Qualifiers
Patients of both sexes recovered from SARS-CoV-2 infection (two negative nasopharyngeal swabs, negative IgM and positive anti SARS-CoV-2 IgG);
Aged over 18 years of age;
Ability to understand protocol procedures
Disqualifiers
Any psychological/psychiatric/other medical conditions compromising the understanding of the nature and purpose of the study, and of its possible consequences
Uncooperative attitude of the patient
Trial design
Treatments tested in this trial
- Assessment of andrological profile of LO-COCO-ANDRO male patients
- Assessment of reproductive function of LO-COCO-ANDRO male patients
- Assessment of sexual function of LO-COCO-ANDRO male patients
- Assessment of olfactory function of LO-COCO-ANDRO male and female patients
Treatment groups
Sponsors and collaborators
Federico II University
Lead sponsor
Azienda Sanitaria Locale Napoli 2 Nord
Collaborator